drugset / Trial / NCT05346354
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).
Timeline
- Start
- 2022-06-23
- Primary completion
- 2026-06-22
- Completion
- 2029-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ravulizumab | Monoclonal antibody | — | Intravenous |